Last reviewed · How we verify
Placebo eye drop
Placebo eye drop is a Small molecule drug developed by Beijing Tongren Hospital. It is currently FDA-approved for Control/comparator agent in clinical trials for ocular conditions. Also known as: 1 drop daily, Hypromellose Ph Eur 0.3g in 100ml, Sodium chloride, Potassium chloride.
A placebo eye drop produces no pharmacological effect and serves as a control or inert comparator in clinical studies.
A placebo eye drop produces no pharmacological effect and serves as a control or inert comparator in clinical studies. Used for Control/comparator agent in clinical trials for ocular conditions.
At a glance
| Generic name | Placebo eye drop |
|---|---|
| Also known as | 1 drop daily, Hypromellose Ph Eur 0.3g in 100ml, Sodium chloride, Potassium chloride, Borax |
| Sponsor | Beijing Tongren Hospital |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Placebo eye drops contain no active pharmaceutical ingredient and work entirely through the placebo effect—patient expectation and psychological factors. They are used in randomized controlled trials to establish the true efficacy of active treatments by providing a baseline against which therapeutic benefit can be measured.
Approved indications
- Control/comparator agent in clinical trials for ocular conditions
Common side effects
Key clinical trials
- Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant (PHASE3)
- Lacripep for Corneal Wound Healing Study (PHASE2)
- FLuorometholone as Adjunctive MEdical Therapy for TT Surgery (FLAME) Trial (PHASE3)
- This is a Single Center, Open-label Prospective Study to Evaluate the Effect of Xiidra® (Lifitegrast Ophthalmic Solution 5.0%) on Tear Film Biomarkers in Dry Eye (PHASE4)
- A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD) (PHASE3)
- Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG) (PHASE2)
- Traditional Chinese Medicine Ultrasonic Atomization Treatment for Dry Eye Disease (NA)
- Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo eye drop CI brief — competitive landscape report
- Placebo eye drop updates RSS · CI watch RSS
- Beijing Tongren Hospital portfolio CI
Frequently asked questions about Placebo eye drop
What is Placebo eye drop?
How does Placebo eye drop work?
What is Placebo eye drop used for?
Who makes Placebo eye drop?
Is Placebo eye drop also known as anything else?
What development phase is Placebo eye drop in?
Related
- Manufacturer: Beijing Tongren Hospital — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Control/comparator agent in clinical trials for ocular conditions
- Also known as: 1 drop daily, Hypromellose Ph Eur 0.3g in 100ml, Sodium chloride, Potassium chloride, Borax
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing